Short answer
Aldeyra Therapeutics, Inc. (ALDX) filed an 8-K current report with the SEC on September 29, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Forward-looking disclosure centers on FDA discussions and reproxalap regulatory pathway.
Aldeyra Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Forward-looking disclosure centers on FDA discussions and reproxalap regulatory pathway
- Potential FDRR submission and NDA resubmission represent key approval catalysts
- FDA acceptance or approval remains uncertain, creating material regulatory risk
- Projected cash runway identified as a forward-looking financial concern
Item EX-99.1 · Exhibit EX-99.1
- Aldeyra plans a Formal Dispute Resolution Request to FDA’s Office of New Drugs after three complete response letters for reproxalap
- OND meeting expected in Q4 2026, but FDRR timing and outcome remain uncertain
- Nine efficacy trials supported the NDA; five achieved all primary endpoints and 9 of 14 endpoints had P<0.05
- FDA’s latest letter cited insufficient totality of evidence without requesting another clinical trial, preserving a potential regulatory path
- $45.1M cash as of June 30, 2026, with company-estimated runway into 2029 supporting FDRR and ADX-2191 development
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aldeyra Therapeutics, Inc. 8-K filings
Get the next ALDX 8-K as it lands
Follow ALDX for push alerts, or ask the research agent what this filing means.